Moyamoya disease can be fatal, but most patients survive for years or even decades, particularly when treated with surgical revascularization. A South Korean study tracking long-term outcomes found ten-year survival rates ranging from about 76% for patients who first presented with hemorrhagic stroke to roughly 94% for those who were asymptomatic at diagnosis. The wide gap between those numbers points to something important: how dangerous moyamoya is depends heavily on how it shows up, how early it is caught, and whether the patient undergoes bypass surgery. The disease is progressive and has no cure, but the outlook has improved substantially as surgical techniques have matured.
How Moyamoya Kills
Moyamoya disease slowly narrows the major arteries feeding the brain, forcing the body to build fragile collateral blood vessels to compensate. Those collaterals are the disease’s signature on imaging, but they are also its Achilles heel. They can rupture and bleed into the brain, or they can fail to deliver enough blood, causing ischemic stroke. Both types of stroke can be fatal.
Hemorrhagic stroke is the leading cause of death. In an early landmark series of 518 patients, intracranial bleeding accounted for death in about 56% of children and 63% of adults who died from the disease. Among adults, the overall mortality rate in that series was 10%, compared with about 4% in children. A more recent study focused specifically on patients who had already suffered one hemorrhagic stroke found that roughly 37% experienced a recurrent bleed over the follow-up period, with an annual rebleeding rate of about 4.5%. Among those who rebled, about one in five died from the event. Rebleeding was far and away the main driver of death in that group, while ischemic stroke was uncommon by comparison.
Survival Rates by How the Disease Presents
Not everyone with moyamoya faces the same level of risk. The type of stroke or symptom that brings a patient to medical attention is one of the strongest predictors of long-term survival. A large South Korean cohort study reported ten-year survival rates stratified by initial presentation: roughly 89% for patients whose disease first appeared as ischemic stroke, about 76% for those who presented with hemorrhagic stroke, and approximately 94% for patients who were asymptomatic or had non-stroke symptoms at diagnosis. The differences were statistically significant and clinically meaningful. Hemorrhagic-onset moyamoya carries the worst prognosis, and asymptomatic patients fare best, though even the asymptomatic group faces a meaningfully higher mortality risk than the general population of the same age.
What About Asymptomatic Patients
Some people learn they have moyamoya incidentally, through imaging done for another reason, or because a family member was diagnosed. The natural question is whether a disease that produces no symptoms still poses a threat. The short answer is yes, though the risk is lower. Data from the Asymptomatic Moyamoya Registry (AMORE) found an annual stroke risk of about 1.4% per person over five years in patients with no prior symptoms. Of the strokes that occurred, most were hemorrhagic rather than ischemic. Specific imaging features, particularly a pattern of collateral vessels called grade-2 choroidal anastomosis, were strong independent predictors of future hemorrhagic stroke. Microbleeds visible on MRI also predicted bleeding events.
An annual stroke risk of 1.4% may sound small in any given year, but compounded over decades in a disease that often strikes young adults and children, it adds up. This is why even asymptomatic patients are typically monitored closely, and some undergo preventive surgery if imaging suggests their collateral circulation is precarious.
How Surgery Changes the Outlook
Surgical revascularization, the main treatment for moyamoya, reroutes blood supply from the external carotid system to the brain, bypassing the narrowed internal carotid arteries. Three broad approaches exist: direct bypass, where a scalp artery is sutured directly to a brain surface artery; indirect bypass, where blood-supply-rich tissue is laid against the brain surface and new vessels grow in over weeks; and combined procedures that use elements of both. A recent meta-analysis reviewed outcomes across more than 11,000 bypass procedures in adults, reflecting how widely these surgeries are now performed.
The survival benefit is substantial. A 2024 study in JAMA Network Open compared bypass surgery against conservative management across different moyamoya subtypes. In hemorrhagic moyamoya, surgery was associated with a halved risk of death and a roughly 64% reduction in hemorrhagic stroke. In ischemic moyamoya, surgery cut ischemic stroke risk by about 45%. Even in asymptomatic patients, bypass was linked to a meaningful reduction in mortality. These findings have reinforced a growing consensus that surgery should be considered broadly, not reserved only for patients who have already suffered a major stroke.
For children, the evidence also favors revascularization. One study found that combined bypass significantly reduced postoperative ischemic events compared with indirect bypass alone, and suggested that surgery may help prevent the intellectual decline that otherwise accompanies the disease in young patients.
Risks of Surgery Itself
Bypass surgery is not without complications. One of the most closely watched is cerebral hyperperfusion syndrome, where the newly revascularized brain tissue receives a sudden surge of blood flow it is not accustomed to. A meta-analysis found that hyperperfusion syndrome occurred in about 16.5% of cases overall, but the rate varied sharply by age: roughly 4% in children versus about 20% in adults. Symptoms typically include sensory changes and weakness on the opposite side of the body, sometimes with language problems, and in rare cases the surge can trigger bleeding.
Hyperperfusion usually resolves within days to a couple of weeks. One study of adult patients found that symptoms appeared around the sixth day after surgery and lasted a median of about a week. Patients whose preoperative imaging showed increased cerebral blood volume were at substantially higher risk, and the syndrome was more likely after direct bypass than after indirect procedures alone. Surgeons use this information to manage blood pressure aggressively in the postoperative period and to counsel patients about what to expect during recovery.
Perioperative stroke is the other major risk. The quality of a patient’s existing collateral circulation influences this: patients with poorer collateral scores before surgery are more likely to suffer a postoperative stroke and tend to have worse overall outcomes.
Living with Moyamoya Beyond Survival
Surviving is one thing; how well someone functions afterward is another, and this is where moyamoya’s toll is often underappreciated. A recent long-term outcome study found that while about 60% of patients achieved what clinicians would call a favorable functional outcome, only 16% of adults were working full time. The authors concluded that the disease considerably impacts daily life for a substantial number of people, with only a minority able to fully provide for themselves financially.
Cognitive problems are a major contributor. In adults, executive function impairment is the most common deficit, affecting roughly 57% of patients in one longitudinal study. Problems with processing speed, visual memory, and performance IQ are also frequent. In children, intelligence is the cognitive domain most affected, which can have cascading effects on school performance and social development. A sobering finding from the adult longitudinal data is that the cognitive profile tends to remain broadly stable over years of follow-up, meaning the deficits that exist after initial treatment typically do not improve much, but they also do not clearly worsen in most patients.
A meta-analysis pooling functional outcomes across multiple studies estimated that about 87% of surgically treated patients achieved a “good outcome” by relatively coarse clinical scales. That number sounds encouraging, but the gap between a “good outcome” on a five-point disability scale and full-time employment or complete cognitive recovery is wide. Rehabilitation can make a real difference: even case reports from resource-limited settings have documented patients returning to work and functional independence after structured rehabilitation programs, though access to such programs varies enormously.
Medical Management and Antiplatelet Therapy
Surgery is the mainstay of treatment, but not every patient is an immediate surgical candidate, and some require medical management either as a bridge or as a complement to revascularization. Antiplatelet drugs are frequently prescribed, though the evidence for them is still evolving and somewhat contradictory.
A nationwide study found that antiplatelet therapy was associated with substantially improved survival in moyamoya patients, with one drug in particular, cilostazol, linked to a greater survival benefit than other antiplatelet regimens. However, a systematic review of the broader literature painted a more ambiguous picture: most individual studies did not demonstrate a clear protective effect of antiplatelet treatment against ischemic stroke, and the impact on functional outcomes was inconclusive. On the reassuring side, none of the studies found that antiplatelet therapy increased the risk of hemorrhagic stroke, which has been a longstanding concern given that many moyamoya patients are vulnerable to bleeding.
A separate meta-analysis added nuance by finding that antiplatelet therapy actually reduced the risk of hemorrhagic stroke, though it did not significantly lower ischemic stroke risk or improve the proportion of patients achieving functional independence. The picture that emerges is that antiplatelets may help some patients stay alive longer, particularly through hemorrhage prevention, but they are not a substitute for surgical revascularization when it is indicated. Randomized controlled trials are still needed to settle the question definitively.
Moyamoya in Pregnancy
Because moyamoya disproportionately affects women of childbearing age, pregnancy is a practical concern that comes up frequently. The hemodynamic stress of pregnancy and delivery raises legitimate worries about stroke risk. A large study published in JAMA Network Open examined stroke risk after childbirth in women with moyamoya and found that stroke incidence peaked sharply in the early postpartum period, roughly within the first six months, at a rate of about 36 per 1,000 person-years. After that initial spike, the risk dropped and then plateaued.
One question many patients and obstetricians have is whether cesarean delivery is safer than vaginal delivery. The study found no significant overall difference in stroke risk between the two modes of birth at either three months or three years postpartum. However, there was a notable interaction with the type of moyamoya: in women whose disease had been asymptomatic or presented without vascular symptoms, vaginal delivery appeared to carry a substantially lower stroke risk than cesarean delivery. In women with hemorrhagic-onset moyamoya, the two delivery modes carried similar risk. The findings do not support a blanket policy of cesarean delivery for all women with moyamoya, though individual circumstances and the subtype of disease should factor into the decision.
Who Gets Moyamoya and Does Geography Matter
Moyamoya is most common in East Asian countries, particularly Japan and Korea, but it occurs worldwide. In the United States, the incidence is much lower, with one estimate putting it at about 0.086 per 100,000. Asian Americans have roughly 4.6 times the incidence of white Americans. African Americans tend to be diagnosed earlier, with a median age of 18 in one analysis. Women outnumber men across nearly all populations studied, with a female-to-male ratio of about 2 to 1.
Geography also shapes how the disease behaves. Asian countries report higher rates of hemorrhagic moyamoya in adults, about 42% in some series, compared with lower hemorrhagic rates among people of Asian descent living in the United States. Ischemic manifestations tend to predominate overall, especially in children regardless of geography, but the hemorrhagic-ischemic balance shifts with both ancestry and environment. In European populations, transient ischemic attacks are more frequent at presentation, and cardiovascular risk factors like hypertension and obesity are more common comorbidities, while diabetes is more often seen in Southeast Asian patients.
The genetic underpinnings help explain some of these patterns. A gene called RNF213 is the principal susceptibility gene identified so far. A specific variant, p.R4810K, has been found in about 56% of moyamoya patients of Asian descent in one ethnically diverse study, but was absent in the 94 non-Asian patients tested. Carriers of this variant tend to develop the disease earlier, have more ischemic symptoms, are more likely to have family members with the disease, and show more involvement of the posterior cerebral artery. The fact that this variant is common in East Asian populations but rare elsewhere helps explain why moyamoya is concentrated in that part of the world, though the gene is neither necessary nor sufficient for developing the disease.
Moyamoya Syndrome Versus Moyamoya Disease
Clinicians draw a distinction between moyamoya disease, which is idiopathic (meaning it arises on its own without a known cause), and moyamoya syndrome, where the same arterial narrowing pattern appears alongside another underlying condition. Conditions relatively commonly linked to moyamoya syndrome include neurofibromatosis type 1, Down syndrome, thyroid disease, and prior cranial radiation therapy. Although moyamoya syndrome shares the same vascular appearance on imaging, the clinical course, natural history, and treatment considerations can differ. This distinction matters for prognosis because the underlying condition in moyamoya syndrome may carry its own risks and may influence how aggressively or conservatively the vascular component is managed.
Advances in Monitoring Disease Progression
One of the challenges with moyamoya is that the disease is progressive, and clinicians need ways to track whether it is advancing before a catastrophic stroke occurs. Vessel wall MRI is emerging as a useful tool. Research has shown that the degree of arterial wall enhancement on MRI varies depending on the patient’s age, which arteries are examined, and the stage of the disease. Enhancement tends to be stronger during the progressive stage of moyamoya, and patients with a history of transient ischemic attacks show more enhancement in the proximal middle cerebral artery, which may serve as a marker that the disease is actively worsening. These imaging advances are not yet standard everywhere, but they represent a move toward catching progression earlier and intervening before irreversible damage occurs.